165 related articles for article (PubMed ID: 20098717)
1. JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.
Edes K; Cassidy P; Shami PJ; Moos PJ
PLoS One; 2010 Jan; 5(1):e8786. PubMed ID: 20098717
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
[TBL] [Abstract][Full Text] [Related]
3. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
Qiu M; Ke L; Zhang S; Zeng X; Fang Z; Liu J
Cancer Chemother Pharmacol; 2017 Aug; 80(2):275-286. PubMed ID: 28608259
[TBL] [Abstract][Full Text] [Related]
4. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer.
Liu B; Huang X; Li Y; Liao W; Li M; Liu Y; He R; Feng D; Zhu R; Kurihara H
BMC Cancer; 2019 Jul; 19(1):645. PubMed ID: 31262254
[TBL] [Abstract][Full Text] [Related]
5. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.
Poerschke RL; Moos PJ
Biochem Pharmacol; 2011 Jan; 81(2):211-21. PubMed ID: 20920480
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
Kaczmarek MZ; Holland RJ; Lavanier SA; Troxler JA; Fesenkova VI; Hanson CA; Cmarik JL; Saavedra JE; Keefer LK; Ruscetti SK
Leuk Res; 2014 Mar; 38(3):377-82. PubMed ID: 24461365
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory nitrosylation of mammalian thioredoxin reductase 1: Molecular characterization and evidence for its functional role in cellular nitroso-redox imbalance.
Engelman R; Ziv T; Arnér ESJ; Benhar M
Free Radic Biol Med; 2016 Aug; 97():375-385. PubMed ID: 27377780
[TBL] [Abstract][Full Text] [Related]
10. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
11. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
12. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
13. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
14. JS-K induces reactive oxygen species-dependent anti-cancer effects by targeting mitochondria respiratory chain complexes in gastric cancer.
Zhao X; Cai A; Peng Z; Liang W; Xi H; Li P; Chen G; Yu J; Chen L
J Cell Mol Med; 2019 Apr; 23(4):2489-2504. PubMed ID: 30672108
[TBL] [Abstract][Full Text] [Related]
15. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V; Saavedra JE; Nieves-Alicea R; Simeone AM; Keefer LK; Tari AM
Int J Oncol; 2011 Apr; 38(4):963-71. PubMed ID: 21271218
[TBL] [Abstract][Full Text] [Related]
16. The Nitric Oxide Prodrug JS-K Induces Ca(2+)-Mediated Apoptosis in Human Hepatocellular Carcinoma HepG2 Cells.
Liu L; Wang D; Wang J; Wang S
J Biochem Mol Toxicol; 2016 Apr; 30(4):192-9. PubMed ID: 26616367
[TBL] [Abstract][Full Text] [Related]
17. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
[TBL] [Abstract][Full Text] [Related]
18. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
Huang Z; Liu L; Chen J; Cao M; Wang J
Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
[TBL] [Abstract][Full Text] [Related]
19. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
